XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of presentation - Schedule of Impact of Restatement on Certain Line Items and Balance Sheet (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]                
Other asset impairments, restructuring and other items [1] $ (23) $ 57 $ 931 $ 276        
Operating income (loss) [1] (51) 344 (274) (323)        
Income (loss) before income taxes [1] (324) 64 (1,037) (1,131)        
Income taxes (benefit) 69 (12) 648 (48)        
Net income (loss) (390) 77 (1,684) (1,082)        
Net income (loss) attributable to Teva $ (437) $ 69 $ (1,422) $ (1,022)        
Earnings (loss) per share attributable to ordinary shareholders:                
Basic $ (0.39) $ 0.06 $ (1.26) $ (0.91)        
Diluted $ (0.39) $ 0.06 $ (1.26) $ (0.91)        
Deferred income taxes $ 2,070 $ 1,755 $ 2,070 $ 1,755   $ 1,812    
Total assets 41,758 42,095 41,758 42,095   43,479    
Other taxes and long-term liabilities 4,344 3,950 4,344 3,950   4,019    
Total long-term liabilities 21,578 23,314 21,578 23,314   23,106    
Total liabilities 35,375 34,708 35,375 34,708   35,353    
Teva shareholders' equity:                
Accumulated deficit (14,956) (13,995) (14,956) (13,995)   (13,534)    
Total equity 6,383 7,387 6,383 7,387 $ 6,563 8,126 $ 7,592 $ 8,598
Total liabilities and equity $ 41,758 42,095 $ 41,758 42,095   $ 43,479    
As previously reported [Member]                
Error Corrections and Prior Period Adjustments Restatement [Line Items]                
Other asset impairments, restructuring and other items   46   241        
Operating income (loss)   355   (289)        
Income (loss) before income taxes   75   (1,097)        
Income taxes (benefit)   (12)   (48)        
Net income (loss)   88   (1,048)        
Net income (loss) attributable to Teva   $ 80   $ (988)        
Earnings (loss) per share attributable to ordinary shareholders:                
Basic   $ 0.07   $ (0.88)        
Diluted   $ 0.07   $ (0.88)        
Deferred income taxes   $ 1,748   $ 1,748        
Total assets   42,088   42,088        
Other taxes and long-term liabilities   3,818   3,818        
Total long-term liabilities   23,182   23,182        
Total liabilities   34,576   34,576        
Teva shareholders' equity:                
Accumulated deficit   (13,870)   (13,870)        
Total equity   7,512   7,512        
Total liabilities and equity   42,088   42,088        
Adjustment [Member]                
Error Corrections and Prior Period Adjustments Restatement [Line Items]                
Other asset impairments, restructuring and other items   11   34        
Operating income (loss)   (11)   (34)        
Income (loss) before income taxes   (11)   (34)        
Net income (loss)   (11)   (34)        
Net income (loss) attributable to Teva   $ (11)   $ (34)        
Earnings (loss) per share attributable to ordinary shareholders:                
Basic   $ (0.01)   $ (0.04)        
Diluted   $ (0.01)   $ (0.04)        
Deferred income taxes   $ 7   $ 7        
Total assets   7   7        
Other taxes and long-term liabilities   132   132        
Total long-term liabilities   132   132        
Total liabilities   132   132        
Teva shareholders' equity:                
Accumulated deficit   (125)   (125)        
Total equity   (125)   (125)        
Total liabilities and equity   $ 7   $ 7        
[1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.